Bioventus Inc. is a global orthobiologics company that provides clinically proven, cost-effective products to help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios, Osteoarthritic (OA) and Bone Graft Substitutes, and Surgical Solutions, that address the continuum of care for patients, from pain relief to joint preservation to joint surgery. The company's products are known for their safety, innovation, and effectiveness.
The Durham headquarters serves as the central hub for Bioventus's global operations, including corporate strategy, research and development leadership, finance, legal, marketing, and administrative functions.
The headquarters is situated in a modern office park, likely featuring contemporary office designs, collaborative workspaces, and potentially lab facilities suited for a life sciences company. Specific architectural awards or unique features are not widely publicized, suggesting a focus on functional and efficient design.
Bioventus fosters a culture centered on innovation, patient outcomes, and ethical practices. The HQ environment likely encourages collaboration, continuous learning, and a strong sense of purpose tied to improving patient lives.
Its location in Durham's Research Triangle Park provides strategic advantages, including access to a rich talent pool from nearby universities (Duke, UNC, NC State), proximity to other life science companies for potential partnerships, and a supportive business ecosystem.
Bioventus supports global functions including research and development, manufacturing, sales and marketing, and distribution. The company has a direct commercial presence in the United States, Canada, Europe (including Netherlands, Germany, UK), and Australia, and also utilizes a network of distributors to reach patients in many other countries worldwide. Key international hubs are located in the Netherlands (for EMEA) and Israel (R&D).
4721 Emperor Blvd, Suite 100
Durham
North Carolina
USA
Address: Specific street address not readily available, likely in an industrial/commercial park.
Supports the efficient distribution of Bioventus products across North America and potentially globally.
Address: MATAM Advanced Technology Park, Haifa, Israel (following acquisition of CartiHeal)
Acts as a significant R&D center, leveraging Israel's robust medtech innovation ecosystem, and supports product development for global markets.
Address: Polarisavenue 33, 2132 JH Hoofddorp, The Netherlands
Manages and expands Bioventus's presence and product distribution outside of the Americas.
Address: 2476 Argentia Road, Suite 100, Mississauga, ON L5N 6M1, Canada
Supports market access and growth within Canada for Bioventus's product portfolio.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Bioventus' leadership includes:
Bioventus has been backed by several prominent investors over the years, including:
Bioventus has experienced notable executive transitions recently, including the appointment of a new President and CEO and a new CFO, signaling a period of leadership refresh and strategic realignment.
Discover the tools Bioventus uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Bioventus commonly uses the first_name.last_name@bioventus.com email format. Variations might exist but this is the most prevalent pattern observed.
first.last@bioventus.com
Format
jane.doe@bioventus.com
Example
90%
Success rate
Bioventus Investor Relations • May 7, 2024
Bioventus announced its financial results for the first quarter ended March 30, 2024, highlighting net sales of $119.1 million and progress on strategic initiatives under new leadership....more
Bioventus Investor Relations • May 20, 2024
Bioventus announced the appointment of Mark Singleton as senior vice president and chief financial officer, effective May 20, 2024. He brings over 25 years of financial leadership experience....more
Bioventus Investor Relations • April 10, 2024
Bioventus announced that its Board of Directors has appointed Robert (Rob) Claypoole as its new president and chief executive officer and a member of the Board, effective April 8, 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Bioventus, are just a search away.